Immuneering Corporation

Biotechnology ResearchMassachusetts, United States51-200 Employees

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes  across  a  spectrum  of  debilitating  oncologic  and  neurologic  diseases  by  applying  its  deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more  than a decade of experience  in translational bioinformatics and generating insights  into drug mechanisms  of  action  and  patient  treatment  responses.  Building  on  this  experience,  Immuneering  has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current  development  programs  in  oncology  are  focused  on  providing  potential  treatments  for  patients with  solid  tumors  caused  by  mutations  of  oncologic  signaling  pathways,  including  the  MAPK  pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors.  Additionally,  Immuneering  has  six  other  oncology  programs  in  the  discovery  stage  that  are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Sign up for free to view info

Email Format Employee directory